Inside the commercial growing pains of hemophilia gene therapies
With Pfizer discontinuing Beqvez and BioMarin scaling back the commercial focus of Roctavian, the curative promise of hemophilia gene therapies is tempered by significant barriers that discourage wide...
12 Syys 202521min
A rare kind of leadership, 30 years in the making
Hope, when applied with purpose and action, can be a powerful force for driving change in healthcare. That’s the philosophy of Eugene Woods, CEO of Advocate Health and a 2025 Fierce 50 honoree, who jo...
5 Syys 202513min
Former FDA Chief Scott Gottlieb talks drug pricing, access and innovation (Sponsored)
In the latest episode of the Health Matters podcast, former Food and Drug Administration Commissioner Scott Gottlieb joins WPP’s Wendy Lund, GCI Health’s Ryan Kuresman and Burson’s Judy Stecker to dis...
1 Syys 202527min
Big Pharma bounces back in Q2
After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the second quarter. In this episode of "The Top Line," F...
22 Elo 202514min
The battle of the obesity drug heavyweights
While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s GLP-1s quarter after quarter, this most recent earnings season delivered a few...
15 Elo 202526min
Is Trump’s MFN pricing order more bark than bite?
Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored Nation drug pricing reforms in the U.S., analysts and industry watchers ar...
8 Elo 202517min
Rebuilding trust: compassionate communication and public health (Sponsored)
In the latest episode of Health Matters, vaccine expert Dr. Paul Offit joins host Wendy Lund to discuss the growing crisis of vaccine hesitancy and what can be done to rebuild trust. Offit, director o...
4 Elo 202539min
Untangling Sarepta’s gene therapy fallout and a growing trust deficit
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy Elevidys and growing scrutiny over the company’s transparency following multiple ...
1 Elo 202527min
